School of Biomedical Sciences
生物醫學學院
The Chinese University of Hong Kong 香港中文大學


He YishengResearch Assistant Professor

BS.c., MS.c., Ph.D.

Telephone:  3943 5726

Email:  This email address is being protected from spambots. You need JavaScript enabled to view it.

Address:

 505, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

ORCID: https://orcid.org/0000-0002-2217-6758

Google Scholar: https://scholar.google.com.hk/citations?user=Qkc6iBwAAAAJ&hl=en

 

 

 

 

Biography

Prof. HE Yisheng (賀益盛) received BSc (Chinese Medicine, 2012) and MSc degrees (Pharmacognosy, 2015) in China Pharmaceutical University, and PhD degree (Biomedical Science, 2018) in The Chinese University of Hong Kong. Thereafter he received postdoctoral training in School of Biomedical Sciences, CUHK. Dr. He focuses on delineating the cellular and molecular basis for the mode-of-action of environmental/natural/chemical toxins (with particular interest in mutagenicity and carcinogenicity), developing and translating molecular biomarkers (chemical-based, genome-based) for clinical and public health use to identify human diseases related to natural toxin exposure, profiling pharmacokinetics of therapeutic biologics and toxicokinetic of natural/chemical toxins, and utilizing modeling and simulation approaches to optimize precision risk assessment/prediction on safety issues of drugs and environmental toxins. Dr. He has published 20 peer-reviewed papers, with some in top journals in the related fields, including Hepatology, Acta Pharmaceutica Sinica B, Environmental Science & Technology Letters, and Archives of Toxicology. His work highlights fundamental-to-applied research on diagnosis, treatment, and prevention of adverse effects caused by drugs and environmental toxins.

  1. Drug-induced liver injury.
  2. Pharmacokinetic and toxicokinetics.
  3. Biomarker development for translational application.
  4. Molecular/mechanistic toxicology.
  5. Analytical chemistry.
  1. He, Y.#, Shi, M.#, Wu, X., Ma, J., Ng, K.T.P., Xia, Q., Zhu, L., Fu, P.P.C., Man, K., Tsui, S.K.W., & Lin, G.* (2021). Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology, 74(1), 264–280.
  2. He, Y.#, Ma, J.#, Fan, X., Ding, L., Ding, X., Zhang, Q.Y.*, & Lin, G.* (2021). The key role of gut-liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity. Acta Pharm. Sin. B., doi: 10.1016/j.apsb.2021.07.013.
  3. He, Y.#, Zhang, W.#, Ma, J.#, Xia, Q., Song, Z., Zhu, L., Zhang, C., Liu, J., Ye, Y., Fu, P.P. and Zhuge, Y.*, & Lin, G.* (2021). Blood pyrrole-DNA adducts define the early tumorigenic risk in patients with pyrrolizidine alkaloid-induced liver injury. Environ. Sci. Technol. Lett., 8(7), 551–557.
  4. He, Y.#, Zhu, L.#, Ma, J. & Lin, G.* (2021). Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Arch. Toxicol., 95(1), 1917–1942.
  5. He, Y.#, Lian, W.#, Ding, L., Fan, X., Ma, J., Zhang, Q.Y., Ding, X.*, & Lin, G.* (2021). Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites. Arch. Toxicol., 95(1), 103–116.
  6. Huang, H., Li, M., Wang, Y., Wu, X., Shen, J., Xiao, Z., Zhao, Y., Du, F., Chen, Y., Wu, Z., Ji, H., Zhang, C., Li, J., Wen, Q., Kaboli, P.J., Cho. C.H., Wang, S.P., Wang, Y., He, Y.*, & Wu. X.* (2021). Excessive intake of longan arillus alters gut homeostasis and aggravates colitis in mice. Front. Pharmacol., 12, 640417.
  7. Ma, J.#, Zhang, W.#, He, Y.#, Zhu, L., Zhang, C., Liu, J., Ye, Y., Zhuge, Y.*, & Lin, G.* (2021). Clinical application of pyrrole-hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Arch. Toxicol., 95(1), 759–765.
  8. He, Y., Zhu, L., Ma, J., Wong, L., Zhao, Z., Ye, Y., Fu, P.P., & Lin, G.* (2020). Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. Environ. Pollut., 267, 115542.
  9. Song, Z.#, He, Y.#, Ma, J., Fu, P.P., & Lin, G*. (2020). Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids. J. Environ. Sci. Heal. C, 38(2), 124–140.
  10. He, Y., Sun, W., Zhang, B.Y., Xu, L.H., Yang, J., Gao, W., Qi, L.W., Li, P.*, & Wen, X.D.* (2016). Application of a sensitive liquid chromatography-mass spectrometry method to a pharmacokinetic study of nerolidol in rat plasma. Anal. Methods-UK, 8(4), 785–789.
  11. He, Y.#, Sun, W.#, Wang, C.Z., Qi, L.W., Yang, J., Li, P.*, Wen, X.D.*, and Yuan, C.S. (2015). Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats. Biomed. Chromatogr., 29(5), 762–767.

*Corresponding / Co-corresponding author
#Co-first author